Switch theme
Sign up to access all valuation multiples
Cementos Bio-Bio SA is a cement manufacturing company. The company manufactures and distributes construction materials.
1957
2.9K+
Last FY Revenue $372M
Last FY EBITDA $56.7M
$618M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Cementos Bio-Bio achieved revenue of $372M and an EBITDA of $56.7M.
Cementos Bio-Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cementos Bio-Bio valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $372M | XXX | XXX | XXX |
| Gross Profit | XXX | $142M | XXX | XXX | XXX |
| Gross Margin | XXX | 38% | XXX | XXX | XXX |
| EBITDA | XXX | $56.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 15% | XXX | XXX | XXX |
| EBIT | XXX | $39.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 11% | XXX | XXX | XXX |
| Net Profit | XXX | $33.5M | XXX | XXX | XXX |
| Net Margin | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | $78.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Cementos Bio-Bio's stock price is CLP 1800 (or $2).
Cementos Bio-Bio has current market cap of CLP 476B (or $491M), and EV of CLP 598B (or $618M).
See Cementos Bio-Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $618M | $491M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Cementos Bio-Bio has market cap of $491M and EV of $618M.
Cementos Bio-Bio's trades at 1.7x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate Cementos Bio-Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cementos Bio-Bio's P/E ratio is not available.
See valuation multiples for Cementos Bio-Bio and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $491M | XXX | $491M | XXX | XXX | XXX |
| EV (current) | $618M | XXX | $618M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 15.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 14.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 11.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCementos Bio-Bio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $35K for the same period.
Cementos Bio-Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cementos Bio-Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cementos Bio-Bio and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| James Hardie | XXX | XXX | XXX | XXX | XXX | XXX |
| MATHIOS REFRACTORY | XXX | XXX | XXX | XXX | XXX | XXX |
| Cementos Argos | XXX | XXX | XXX | XXX | XXX | XXX |
| Grupo Argos | XXX | XXX | XXX | XXX | XXX | XXX |
| Ambuja Cements | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cementos Bio-Bio acquired XXX companies to date.
Last acquisition by Cementos Bio-Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Cementos Bio-Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Cementos Bio-Bio founded? | Cementos Bio-Bio was founded in 1957. |
| Where is Cementos Bio-Bio headquartered? | Cementos Bio-Bio is headquartered in Chile. |
| How many employees does Cementos Bio-Bio have? | As of today, Cementos Bio-Bio has 2.9K+ employees. |
| Is Cementos Bio-Bio publicy listed? | Yes, Cementos Bio-Bio is a public company listed on SGO. |
| What is the stock symbol of Cementos Bio-Bio? | Cementos Bio-Bio trades under CEMENTOS ticker. |
| When did Cementos Bio-Bio go public? | Cementos Bio-Bio went public in 1982. |
| Who are competitors of Cementos Bio-Bio? | Similar companies to Cementos Bio-Bio include e.g. James Hardie, MATHIOS REFRACTORY, Cementos Argos, Grupo Argos. |
| What is the current market cap of Cementos Bio-Bio? | Cementos Bio-Bio's current market cap is $491M |
| Is Cementos Bio-Bio profitable? | Yes, Cementos Bio-Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
